Healthcare Industry News: Artio Medical
News Release - June 16, 2022
Artio Medical Closes $28M in Additional Series A FinancingFunding to launch commercial sales team in US and continue development of best-in-class product pipeline
PRAIRIE VILLAGE, Kan., June 16, 2022 -- (Healthcare Sales & Marketing Network) -- Artio Medical, Inc., a medical device company developing innovative products for the peripheral vascular, neurovascular, and cardiology markets, today announced the closing of $28 million in oversubscribed Series A2 and Series A3 financing, bringing the total amount raised to date to $74 million. Funds will be used to support US commercialization efforts for the recently cleared Solus Gold™ Embolization Device and to accelerate the development of Artio's broad portfolio of products, including expanding the Company's engineering and manufacturing capabilities.
"We would like to thank our existing investors for their continued strong support and also welcome a new group of investors to Artio," stated Joseph McConnell, Vice President of Finance and Business Operations at Artio. "We have the opportunity to do something really special here, to bring a new generation of medical devices to market with the potential to save lives, reduce disability, and improve the quality of life for millions of people. This new capital will help Artio expand our team and scale our operations to deliver on that mission."
About Artio Medical
Artio Medical is a medical device company committed to developing innovative products for the treatment of peripheral vascular, neurovascular, and cardiovascular diseases. For more information, please visit www.artiomedical.com.
Source: Artio Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.